Treatment of chronic HBV infection in developing countries
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 6
Abstract
Due to virological, host and socio-economic factors, the clinical presentation and treatment of chronic hepatitis B (CHB) differs between developing and developed countries and may differ between one low-income country and another. National healthcare prevention and treatment policies, environmental factors, social habits and personal life-styles all influence HBV transmission and the clinical management and therapy of CHB. These factors can have a strong impact on the natural history of the disease and on Access to treatment and may eventually determine substantial changes in disease progression and the development of serious complications and hepatocellular carcinoma. In this review article, we analyze the clinical characteristics and access to antiviral treatment of CHB patients in low-income countries in Africa, Asia, Eastern Europe and Latin America.
Authors and Affiliations
Rosa Zampino, Caterina Sagnelli, Adriana Boemio, Evangelista Sagnelli, Nicola Coppola
Keywords
Related Articles
- EP ID EP207219
- DOI -
- Views 107
- Downloads 0
NISCH syndrome with hypothyroxinemia
Neonatal Ichthyosis Sclerosing Cholangitis (NISCH) syndrome is a rare autosomal recessive condition characterized by ichthyosis, sclerosing cholangitis and alopecia. Only 5 patients have been described till now. We repor...
SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women
Background and aims. Secreted frizzled-related protein 5 (SFRP5) was recently described as a new adipokine protective for hepatic steatosis and other obesity-related complications in the mouse model. To date, SFRP5 expre...
Hepatitis B viral load and risk of HBV-related liver disease: from East to West?
Chronic hepatitis B has a variable course in disease activity with a risk of clinical complications like liver cirrhosis and hepatocellular carcinoma. As clinical symptoms present in a late stage of the disease, identifi...
Early allograft dysfunction after liver transplantation: an intermediate outcome measure for targeted improvements
Background. The term early allograft dysfunction (EAD) identifies liver transplant (LT) allografts with initial poor function and portends poor allograft and patient survival. Aims of this study are to use EAD as an inte...
PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus
Background. The protein encoded by PARK2 gene is a component of the ubiquitin-proteasome system that mediates targeting of proteins for the degradation pathway. Genetic variations at PARK2 gene were linked to various di...